Arcus Biosciences, Inc. Debt Securities, Available-for-sale, Noncurrent
Arcus Biosciences, Inc. (RCUS) had Debt Securities, Available-for-sale, Noncurrent of $73.00 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent · last filed 2026-08-05
- 2026-06-30: Debt Securities, Available-for-sale, Noncurrent $73.00M.
- 2026-03-31: Debt Securities, Available-for-sale, Noncurrent $54.00M.
- 2025-12-31: Debt Securities, Available-for-sale, Noncurrent $29.00M.
- 2025-09-30: Debt Securities, Available-for-sale, Noncurrent $10.00M.
| Period end | Debt Securities, Available-for-sale, Noncurrent | Debt Securities, Available-for-sale, Noncurrent as first filed |
|---|---|---|
| 2026-06-30 | $73.00M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $54.00M 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $29.00M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $10.00M 10-Q · filed 2025-10-28 | |
| 2025-06-30 | $16.00M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $8.00M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $14.00M 10-K · filed 2026-02-25 | |
| 2024-09-30 | $2.00M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $40.00M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $100.00M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $107.00M 10-K · filed 2025-02-25 | |
| 2023-09-30 | $151.00M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $80.00M 10-Q · filed 2023-08-07 | |
| 2023-03-31 | $90.00M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $129.00M 10-K · filed 2024-02-21 | |
| 2022-09-30 | $143.14M 10-Q · filed 2022-11-02 | |
| 2022-06-30 | $98.33M 10-Q · filed 2022-08-03 | |
| 2022-03-31 | $128.84M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $182.00M 10-K · filed 2023-02-28 | $181.99M 10-K · filed 2022-02-23 |
| 2021-09-30 | $218.73M 10-Q · filed 2021-11-08 | |
| 2021-06-30 | $84.10M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $57.99M 10-Q · filed 2021-05-05 | |
| 2020-12-31 | $6.44M 10-K · filed 2022-02-23 | |
| 2020-09-30 | $2.70M 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |